Abeona Therapeutics Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $7.51 (market cap $421.19M), while Vanguard Real Estate Index Fund ETF trades at $97.12. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | VNQ | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $100.95 |
52-Week Low | $4.17 | $87.00 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
VNQ, the Vanguard Real Estate ETF, trades at $97.13, up 0.02% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. The ETF offers a dividend of $0.86 scheduled for June 2026, but key valuation ratios like P/E and P/B are unavailable. Recent news highlights institutional selling and comparisons with global real estate ETFs, emphasizing VNQ's U.S. REIT focus and low fees.
Outlook: VNQ faces headwinds from bearish technicals and institutional outflows, but its low expense ratio and U.S. real estate exposure provide stability. Risks include interest rate sensitivity and underperformance versus broader markets, as noted in long-term return comparisons. Investors should weigh dividend income against sector volatility and macroeconomic factors.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →